Proactive investorsLogo Proactive Investors UK Website

Search field

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Epic & Msn data
Epic ATD
Time: 16:53:51
Mid Price: 18.00
Change Today: 0.00
Change % Today: -0.00
Fifty Two Week High: 28.50
Fifty Two Week Low: 14.50
Market Capital: 20.93
Period & price data
Period Price
Now: 18.00
3 Months ago:
6 Months ago:
1 Year ago:
Additional information
Additional Information
Market: LSE
Sector: Pharmaceuticals & Biotechnology
Epic: ATD
News: Latest news
Web Site: Asterand
Other Articles: 18-02-201009-02-201004-02-2010

Asterand

Asterand plc is the leading global supplier of high quality, well characterized human tissue and human tissue-based research services to drug discovery scientists. Their mission is to provide human tissues and services to accelerate the identification and validation of drug targets and enhance the selection of drug candidates with an increased likelihood of clinical success.

CLICK HERE FOR FULL ANLAYSIS OF ASTERAND
Wednesday, December 16, 2009

Asterand CEO Martyn Coombs discusses recent acquisition and partnering with Bristol-Myers Squibb

Martyn Coombs, CEO of Asterand, talks about a growth stock that is profitable and positioned in an area where there are barriers to entry, one of the ten ideas that are changing the world right now, collaboration with Bristol-Myers Squibb, and acquiring a company with the same target customer base

 

This Interview was recorded 1st December 2009

 

 

NewsNow icon AddThis Feed Button
Register here to be notified of future Asterand articles.

Other Asterand articles

More articles ►

Other Asterand news

More news ►

Investors interested in Asterand recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.